Drug Profile
Reteplase biosimilar - Reliance Life Sciences
Alternative Names: MiRel; R TPR 004Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Reliance Life Sciences
- Class Plasminogen activator enzymes; Recombinant proteins; Thrombolytics; Vascular disorder therapies
- Mechanism of Action Plasminogen activator stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Myocardial infarction
- Discontinued Stroke
Most Recent Events
- 28 Sep 2021 Discontinued - Phase-II for Stroke in India (IV)
- 16 Dec 2015 No development reported - Phase-II for Stroke in India (IV)
- 06 May 2013 Phase-II clinical trials in Stroke in India (IV)